Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid arthritis / ultrasonography / synovitis
Brief summary
This study compares different methods of clinical evaluation (C) and/or ultrasound (B or D) concerning the rheumatoid arthritis in order to monitore the treatment. This study will provide the exact number of patients in remission according the 3 methods. It could allow to assess the concordance between the 3 evaluated methods. This study will permit to define the best method which limit the evolution of structural damages ( principal criteria).
Detailed description
The aim of this study is to evaluate the Xrays evolution at 1 year ( at least one new erosion versus no erosion with the Sharp modified by van der Heijde) of patients affected by rheumatoid arthritis (ACR/EULAR 2010). The first approach is the assessment of remission defined by modified SDAI in order to evaluate in all cases the same number of joints \[Simplified Disease Activity Index algebric sum of 5 parametres : number of painful joints (28 joints) , number of synovitis (38 joints), global evaluation of patient and and practitioner with VAS, and PCR ≤ 3.3mg/l\] (mode C). The second one is a combined approach: clinical-ultrasound (same criteria but with MTPs and shoulders in B mode so a 26 joints evaluation with clinical examination and 12 joints evaluation in B mode) (mode B). The last one is an ultrasound approach (remission defined as the absence of power Doppler on 38 joints (28 of SDAI plus 10 MTPs joints) (mode D) in a pragmatical context (study assessed by private rheumatologists and hospital rheumatologists). This trial is a National randomized multicentre trial that compares three modes of follow to adjust the therapeutic adaptation in Rheumatoid Artritis.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Inclusion Criteria: * Both gender patients aged 18 -to 80 years old * Patients will be eligible if they fulfill ACR/EULAR 2010 rheumatoid arthritis * All the treatment recommended for rheumatoïd arthritis (anti-inflammatory drugs, steroids, hydroxychloroquine, salazopyrine, methotrexate, ARAVA or biologics treatment: Enbrel, humira, remicade, cimzia, tocilizumab, rituximab, abatacept, simponi) would be in stable posology since at least 12 weeks before inclusion * Patients would be able to understand and be agree with the protocole * Patients would be able to consent *
Exclusion criteria
* Patient unable to cooperate patient and who refuse to sign consent form * Patient unable to understand the study,under administrative supervision or legal guardianship * Signs and symptoms of uncontroled or severe progressive pathology at the level of renal, hepatic, hematological, endocrine, lung, cardiac, neurological or cerebral * Scheduled surgery procedure during the study on the estimated joint. * Patient non-affiliated to social security * Pregnant and nursing mothers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessement of the Xrays evolution at 1 year through adaptated treatment according to clinical or ultrasound remission criteria. | 1 year | The primary outcome is to evaluate the Xrays evolution at 1 year ( at least one new erosion versus no erosion with the Sharp modified by van der Heijde) of rheumatoid arthritis patients (ACR/EULAR 2010) according to remission defined by modified SDAI in order to evaluate in all cases the same number of joints \[Simplified Disease Activity Index algebric sum of 5 parametres : number of painful joints (28 joints) , number of synovitis (38 joints), global evaluation of patient and practitioner with VAS, and PCR ≤ 3.3mg/l\] (mode C), with a combined approach clinical-ultrasound (same criteria but with MTPs and shoulders in B mode so a 26 joints evaluation with clinical examination and 12 joints evaluation in B mode) (mode B) or an ultrasound approach (remission défined as the absence of power Doppler on 38 joints (28 of SDAI plus 10 MTPs joints) (mode D) in a pragmatical context (study assessed by private rheumatologists and hospital rheumatologists). |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the proportion of rheumatoid arthristis in remission according to the method used | at 3 month, 6 month, 9 month and 1 year |
| Assessement of the Xrays evolution at 2 years | 2 years |
Countries
France